Following this strategy, TNF fusion proteins NGR‐TNF, targeting the neovasculature marker aminopeptidase N/CD13, and L19‐TNF, targeting an oncofetal splice variant of fibronectin, are currently in clinical development for the treatment of mesothelioma and melanoma, respectively (Danielli et al, 2015a; Gregorc et al, 2018). This evidence concerns the gene RTN4R and mesothelioma.